Crompton BD, Carlton AL, Thorner AR, et al. High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma. Cancer Res. 2013;73(9):2873-83. doi:10.1158/0008-5472.CAN-12-1944
Knoechel B, Roderick JE, Williamson KE, et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat Genet. 2014;46(4):364-70. doi:10.1038/ng.2913
Lassen KG, Kuballa P, Conway KL, et al. Atg16L1 T300A variant decreases selective autophagy resulting in altered cytokine signaling and decreased antibacterial defense. Proc Natl Acad Sci U S A. 2014;111(21):7741-6. doi:10.1073/pnas.1407001111
Placke T, Faber K, Nonami A, et al. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood. 2014;124(1):13-23. doi:10.1182/blood-2014-02-558114
Pyne S, Hu X, Wang K, et al. Automated high-dimensional flow cytometric data analysis. Proc Natl Acad Sci U S A. 2009;106(21):8519-24. doi:10.1073/pnas.0903028106
Shaul YD, Freinkman E, Comb WC, et al. Dihydropyrimidine accumulation is required for the epithelial-mesenchymal transition. Cell. 2014;158(5):1094-109. doi:10.1016/j.cell.2014.07.032
Doench JG, Hartenian E, Graham DB, et al. Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat Biotechnol. 2014;32(12):1262-7. doi:10.1038/nbt.3026
Schneider RK, Ademà V, Heckl D, et al. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell. 2014;26(4):509-20. doi:10.1016/j.ccr.2014.08.001
Chen E, Schneider RK, Breyfogle LJ, et al. Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms. Blood. 2015;125(2):327-35. doi:10.1182/blood-2014-04-567024
Woodard CM, Campos BA, Kuo SH, et al. iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson’s disease. Cell Rep. 2014;9(4):1173-82. doi:10.1016/j.celrep.2014.10.023